These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 30920963)
1. Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene. Thomsen C; Nielsen S; Nielsen BS; Pedersen SH; Vyberg M Appl Immunohistochem Mol Morphol; 2020; 28(5):347-353. PubMed ID: 30920963 [TBL] [Abstract][Full Text] [Related]
2. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382 [TBL] [Abstract][Full Text] [Related]
3. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors. Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582 [TBL] [Abstract][Full Text] [Related]
4. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882 [TBL] [Abstract][Full Text] [Related]
5. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700 [TBL] [Abstract][Full Text] [Related]
6. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205 [TBL] [Abstract][Full Text] [Related]
7. Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. Bordeaux JM; Cheng H; Welsh AW; Haffty BG; Lannin DR; Wu X; Su N; Ma XJ; Luo Y; Rimm DL PLoS One; 2012; 7(5):e36559. PubMed ID: 22606272 [TBL] [Abstract][Full Text] [Related]
8. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer. Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315 [TBL] [Abstract][Full Text] [Related]
9. Detection of Gene Amplification by Multiplex Ligation-Dependent Probe Amplification in Comparison with In Situ Hybridization and Immunohistochemistry. Tabarestani S; Ghaderian SM; Rezvani H Asian Pac J Cancer Prev; 2015; 16(17):7997-8002. PubMed ID: 26625832 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010 [TBL] [Abstract][Full Text] [Related]
11. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases. Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491 [TBL] [Abstract][Full Text] [Related]
12. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. Bankhead P; Fernández JA; McArt DG; Boyle DP; Li G; Loughrey MB; Irwin GW; Harkin DP; James JA; McQuaid S; Salto-Tellez M; Hamilton PW Lab Invest; 2018 Jan; 98(1):15-26. PubMed ID: 29251737 [TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor alpha (ER alpha) mRNA copy numbers in immunohistochemically ER alpha-positive-, and negative breast cancer tissues. Poola I; Yue Q BMC Cancer; 2007 Mar; 7():56. PubMed ID: 17391528 [TBL] [Abstract][Full Text] [Related]
14. ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. Laenkholm AV; Knoop A; Ejlertsen B; Rudbeck T; Jensen MB; Müller S; Lykkesfeldt AE; Rasmussen BB; Nielsen KV Mol Oncol; 2012 Aug; 6(4):428-36. PubMed ID: 22626971 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. Iwamoto T; Booser D; Valero V; Murray JL; Koenig K; Esteva FJ; Ueno NT; Zhang J; Shi W; Qi Y; Matsuoka J; Yang EJ; Hortobagyi GN; Hatzis C; Symmans WF; Pusztai L J Clin Oncol; 2012 Mar; 30(7):729-34. PubMed ID: 22291085 [TBL] [Abstract][Full Text] [Related]
16. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750 [TBL] [Abstract][Full Text] [Related]
17. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer. Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889 [TBL] [Abstract][Full Text] [Related]
18. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414 [TBL] [Abstract][Full Text] [Related]
19. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas. Coppock JD; Volaric AK; Mills AM; Gru AA Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155 [TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor α (ERα) status evaluation using RNAscope in situ hybridization: a reliable and complementary method for IHC in breast cancer tissues. Yu X; Guo S; Song W; Xiang T; Yang C; Tao K; Zhou L; Cao Y; Liu S Hum Pathol; 2017 Mar; 61():121-129. PubMed ID: 27993577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]